Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity

Journal of Neurochemistry

Volumn 134, Issue 4, 2015, Pages 756-768

  Im, Eunju ^a   Chung, Kwang Chul ^a  

^a Yonsei University   (South Korea)

Author keywords

Dyrk1A; parkin; Parkinson's disease; phosphorylation; TRAF2; UbcH8; ubiquitin E3 ligase

Indexed keywords

DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; PARKIN; PHOSPHOTRANSFERASE; SERINE; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; DYRK KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAMMAL CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SH SY5Y CELL LINE; BRAIN; ENZYME ACTIVATION; HEK293 CELL LINE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

MAMMALIA;

BRAIN; CELL LINE, TUMOR; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; SERINE; UBIQUITIN-PROTEIN LIGASES;

EID: 84937975238     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13164     Document Type: Article

References (45)

1. Becker W., Weber Y., Wetzel K., Eirmbter K., Tejedor F. J., and, Joost H. G., (1998) Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J. Biol. Chem. 273, 25893-25902.
2. Chaugule V. K., Burchell L., Barber K. R., Sidhu A., Leslie S. J., Shaw G. S., and, Walden H., (2011) Autoregulation of parkin activity through its ubiquitin-like domain. EMBO J. 30, 2853-2867.
3. Chung K. K., Thomas B., Li X., Pletnikova O., Troncoso J. C., Marsh L., Dawson V. L., and, Dawson T. M., (2004). S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304, 1328-1331.
4. Chung J. Y., Park H. R., Lee S. J., et al,. (2013) Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of parkin E3 ligase activity. Lab. Invest. 96, 663-676.
5. von Coelln R., Dawson V. L., and, Dawson T. M., (2004) Parkin-associated Parkinson's disease. Cell Tissue Res. 318, 175-184.
6. Dächsel J. C., Lücking C. B., Deeg S., et al,. (2005) Parkin interacts with the proteasome subunit alpha4. FEBS Lett. 579, 3913-3919.
7. Dawson T. M., and, Dawson V. L., (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111, 145-151.
8. Hampe C., Ardila-Osorio H., Fournier M., Brice A., and, Corti O., (2006) Biochemical analysis of Parkinson's disease-causing variants of parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 15, 2059-2075.
9. Henn I. H., Bouman L., Schlehe J. S., et al,. (2007) Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 27, 1868-1878.
10. Himpel S., Tegge W., Frank R., Leder S., Joost H. G., and, Becker W., (2000) Specificity determinants of substrate recognition by the protein kinase DYRK1A. J. Biol. Chem. 275, 2431-2438.
11. Himpel S., Panzer P., Eirmbter K., et al,. (2001) Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem. J. 359, 497-505.
12. Hristova V. A., Beasley S. A., Rylett R. J., and, Shaw G. S., (2009) Identification of a novel Zn2 + -binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin. J. Biol. Chem. 284, 14978-14986.
13. Jiang H., Ren Y., Zhao J., and, Feng J., (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 13, 1745-1754.
14. Joch M., Ase A. R., Chen C. X., MacDonald P. A., Kontogiannea M., Corera A. T., Brice A., Séguéla P., and, Fon E. A., (2007) Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol. Biol. Cell 18, 3105-3118.
15. Kahns S., Lykkebo S., Jakobsen L. D., Nielsen M. S., and, Jensen P. H., (2002) Caspase-mediated parkin cleavage in apoptotic cell death. J. Biol. Chem. 277, 15303-15308.
16. Kalia S. K., Lee S., Smith P. D., Liu L., Crocker S. J., Thorarinsdottir T. E., Glover J. R., Fon E. A., Park D. S., and, Lozano A. M., (2004) BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 44, 931-945.
17. Kim E. J., Sung J. Y., Lee H. J., Rhim H., Hasegawa M., Iwatsubo T., Min do S., Kim J., Paik S. R., and, Chung K. C., (2006). Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J. Biol. Chem. 281, 33250-33257.
18. Kim Y., Park J., Kim S., Song S., Kwon S. K., Lee S. H., Kitada T., Kim J. M., and, Chung J., (2008) PINK1 controls mitochondrial localization of parkin through direct phosphorylation. Biochem. Biophys. Res. Commun. 377, 975-980.
19. Ko H. S., Lee Y., Shin J. H., Karuppagounder S. S., Gadad B. S., Koleske A. J., Pletnikova O., Troncoso J. C., Dawson V. L., and, Dawson T. M., (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc. Natl Acad. Sci. USA 107, 16691-16696.
20. Kondapalli C., Kazlauskaite A., Zhang N., et al,. (2012) PINK1 is activated by mitochondrial membrane potential depolarization and stimulates parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2, 120080.
21. LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G., and, Selkoe D. J., (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214-1221.
22. Lorick K. L., Jensen J. P., Fang S., Ong A. M., Hatakeyama S., and, Weissman A. M., (1999) RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl Acad. Sci. USA 96, 11364-11369.
23. McNaught K. S., and, Olanow C. W., (2003) Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 53 (S73-84), S84-S86.
24. Ogawa Y., Nonaka Y., Goto T., et al,. (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat. Commun. 1, 86.
25. Park J., and, Chung K. C., (2013) New perspectives of Dyrk1A role in neurogenesis and neuropathologic features of Down syndrome. Exp. Neurobiol. 22, 244-248.
26. Park J., Yang E. J., Yoon J. H., and, Chung K. C., (2007) Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome. Mol. Cell Neurosci. 36, 270-279.
27. Park J., Song W. J., and, Chung K. C., (2009) Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell. Mol. Life Sci. 66, 3235-3240.
28. Park J., Oh Y., Yoo L., Jung M. S., Song W. J., Lee S. H., Seo H., and, Chung K. C., (2010) Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J. Biol. Chem. 285, 31895-31906.
29. Park J., Sung J. Y., Park J., Song W. J., Chang S., and, Chung K. C., (2012) Dyrk1A negatively regulates the actin cytoskeleton through threonine phosphorylation of N-WAST. J. Cell Sci. 125, 67-80.
30. Rubio de la Torre E., Luzõn-Toro B., Forte-Lago I., Minguez-Castellanos A., Ferrer I., and, Hilfiker S., (2009) Combined kinase inhibition modulates parkin inactivation. Hum. Mol. Genet. 18, 809-823.
31. Rubio de la Torre E., Gõmez-Suaga P., Martínez-Salvador M., and, Hilfiker S., (2011) Posttranslational modifications as versatile regulators of parkin function. Curr. Med. Chem. 18, 2477-2485.
32. Ryoo S. R., Cho H. J., Lee H. W., et al,. (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J. Neurochem. 104, 1333-1344.
33. Ryu Y. S., Park S. Y., Jung M. S., et al,. (2010) Dryk1A-mediated phosphorylation of Presenilin1: a functional link between Down syndrome and Alzheimer's disease. J. Neurochem. 115, 574-584.
34. Sakata E., Yamaguchi Y., Kurimoto E., et al,. (2003) Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 4, 301-306.
35. Sandebring A., and, Cedazo-Minguez A., (2012) Parkin-an E3 ubiquitin ligase with multiple substrates. J. Alzheimers Dis. Parkinsonism S10, 002.
36. Sato S., Chiba T., Sakata E., Kato K., Mizuno Y., Hattori N., and, Tanaka K., (2006) 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J. 25, 211-221.
37. Shimura H., Hattori N., Kubo S., et al,. (2000) Familial Parkinson disease gene product, parkin, is an ubiquitin-protein ligase. Nat. Genet. 25, 302-305.
38. Tan E. K., and, Skipper L. M., (2007) Pathogenic mutations in Parkinson disease. Hum. Mutat. 28, 641-653.
39. Trempe J. F., Sauvé V., Grenier K., et al,. (2013) Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 340, 1451-1455.
40. Um J. W., and, Chung K. C., (2006) Functional modulation of parkin through physical interaction with SUMO-1. J. Neurosci. Res. 84, 1543-1554.
41. Um J. W., Im E., Lee H. J., Yoo L., Yoo J., Lübbert H., Stichel-Gunkel C., Cho H. S., Yoon J. B., and, Chung K. C., (2010) Parkin directly modulates 26S proteasome activity. J. Neurosci. 30, 11805-11814.
42. Um J. W., Han K. A., Im E., Oh Y., Lee K., and, Chung K. C., (2012) Neddylation positively regulates the ubiquitin E3 ligase activity of parkin. J. Neurosci. Res. 90, 1030-1042.
43. Vandiver M. S., Paul B. D., Xu R., et al,. (2013) Sulfhydration mediates neuroprotective actions of parkin. Nat. Commun. 4, 1626.
44. Wegiel J., Dowjat K., Kaczmarski W., et al,. (2008) The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol. 116, 391-407.
45. Yamamoto A., Friedlein A., Imai Y., Takahashi R., Kahle P. J., and, Haass C., (2005) Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J. Biol. Chem. 280, 3390-3399.